Conclusion
cancer, thrombocytopenia
CANCER, THROMBOCYTOPENIA
Our findings proved that famotidine was an effective radioprotector in terms of the lymphocyte and platelet counts, so that at the end of the study patients in famotidine group showed significantly higher frequencies of lymphocytes and platelets. Besides, in the famotidine group, a significant reduction in thrombocytopenia was observed. To the best of the author’s knowledge, there is a small number of studies to assess famotidine as a radioprotector, most of which are in vivo. Therefore, drawing a favorable comparison between the existing evidence and the results we secured in this study is somewhat difficult. We recommend conducting further research studies and clinical trials in various cancer patient populations using different doses of famotidine or a combination of radioprotective agents to suggest an optimum dose and provide more information about the possible side effects of such drugs in different populations and conditions.